de Bruin Elza C, Taylor Tiffany B, Swanton Charles
Translational Cancer Therapeutics Lab, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
School of Biological Sciences, University of Reading, Whiteknights, Reading, Berkshire RG6 6AH, UK.
Genome Med. 2013 Nov 22;5(11):101. doi: 10.1186/gm505. eCollection 2013.
Multiple subclonal populations of tumor cells can coexist within the same tumor. This intra-tumor heterogeneity will have clinical implications and it is therefore important to identify factors that drive or suppress such heterogeneous tumor progression. Evolutionary biology can provide important insights into this process. In particular, experimental evolution studies of microbial populations, which exist as clonal populations that can diversify into multiple subclones, have revealed important evolutionary processes driving heterogeneity within a population. There are transferrable lessons that can be learnt from these studies that will help us to understand the process of intra-tumor heterogeneity in the clinical setting. In this review, we summarize drivers of microbial diversity that have been identified, such as mutation rate and environmental influences, and discuss how knowledge gained from microbial experimental evolution studies may guide us to identify and understand important selective factors that promote intra-tumor heterogeneity. Furthermore, we discuss how these factors could be used to direct and optimize research efforts to improve patient care, focusing on therapeutic resistance. Finally, we emphasize the need for longitudinal studies to address the impact of these potential tumor heterogeneity-promoting factors on drug resistance, metastatic potential and clinical outcome.
多个肿瘤细胞亚克隆群体可在同一肿瘤内共存。这种肿瘤内异质性具有临床意义,因此识别驱动或抑制这种异质性肿瘤进展的因素很重要。进化生物学可以为这一过程提供重要见解。特别是,微生物群体的实验进化研究表明,作为可以分化为多个亚克隆的克隆群体存在的微生物群体,揭示了驱动群体内异质性的重要进化过程。从这些研究中可以学到一些可迁移的经验教训,这将有助于我们在临床环境中理解肿瘤内异质性的过程。在这篇综述中,我们总结了已确定的微生物多样性驱动因素,如突变率和环境影响,并讨论了从微生物实验进化研究中获得的知识如何指导我们识别和理解促进肿瘤内异质性的重要选择因素。此外,我们讨论了如何利用这些因素来指导和优化研究工作以改善患者护理,重点是治疗抗性。最后,我们强调需要进行纵向研究,以解决这些潜在的肿瘤异质性促进因素对耐药性、转移潜力和临床结果的影响。